6533b7d3fe1ef96bd126140d
RESEARCH PRODUCT
The Crosstalk Between Signaling Pathways and Cancer Metabolism in Colorectal Cancer.
Kha Wai HonIekhsan OthmanSyafiq Asnawi Zainal AbidinRakesh Naidusubject
PharmacologyGlutaminolysisCancercolorectal cancerprotein kinaseRM1-950Tumor initiationReviewBiologymedicine.diseasedigestive system diseasessignaling pathwaysMetastasisCrosstalk (biology)Cancer cellCancer researchmedicinemetabolic reprogrammingPharmacology (medical)Therapeutics. PharmacologySignal transductionReprogrammingmetabolismdescription
Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide. Metabolic reprogramming represents an important cancer hallmark in CRC. Reprogramming core metabolic pathways in cancer cells, such as glycolysis, glutaminolysis, oxidative phosphorylation, and lipid metabolism, is essential to increase energy production and biosynthesis of precursors required to support tumor initiation and progression. Accumulating evidence demonstrates that activation of oncogenes and loss of tumor suppressor genes regulate metabolic reprogramming through the downstream signaling pathways. Protein kinases, such as AKT and c-MYC, are the integral components that facilitate the crosstalk between signaling pathways and metabolic pathways in CRC. This review provides an insight into the crosstalk between signaling pathways and metabolic reprogramming in CRC. Targeting CRC metabolism could open a new avenue for developing CRC therapy by discovering metabolic inhibitors and repurposing protein kinase inhibitors/monoclonal antibodies.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-11-23 | Frontiers in pharmacology |